Jennette C, et al. 2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013; 65:1–11. doi: 10.1002/art.37715

• PubMed
Jennette C, 2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013; 65:1–11. doi: 10.1002/art.37715)| false
• Search Google Scholar
• Export Citation

Segelmark M, Hellmark T. Anti-glomerular basement membrane disease: An update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant 2019; 34:1826–1832. doi: 10.1093/ndt/gfy327

• PubMed
Segelmark M, Hellmark T. Anti-glomerular basement membrane disease: An update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant 2019; 34:1826–1832. doi: 10.1093/ndt/gfy327)| false
• Search Google Scholar
• Export Citation

Savage CO, et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986; 292:301–304. doi: 10.1136/bmj.292.6516.301

• PubMed
Savage CO, Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986; 292:301–304. doi: 10.1136/bmj.292.6516.301)| false
• Search Google Scholar
• Export Citation

Marques C, et al. Prognostic factors in anti-glomerular basement membrane disease: A multicenter study of 119 patients. Front Immunol 2019; 10:1665. doi: 10.3389/fimmu.2019.01665

• PubMed
Marques C, Prognostic factors in anti-glomerular basement membrane disease: A multicenter study of 119 patients. Front Immunol 2019; 10:1665. doi: 10.3389/fimmu.2019.01665)| false
• Search Google Scholar
• Export Citation

van Daalen EE, et al. Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol 2018; 13:63–72. doi: 10.2215/CJN.04290417

• PubMed
van Daalen EE, Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol 2018; 13:63–72. doi: 10.2215/CJN.04290417)| false
• Search Google Scholar
• Export Citation

Alchi B, et al. Predictors of renal and patient outcomes in anti-GBM disease: Clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant 2015; 30:814–821. doi: 10.1093/ndt/gfu399

• PubMed
Alchi B, Predictors of renal and patient outcomes in anti-GBM disease: Clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant 2015; 30:814–821. doi: 10.1093/ndt/gfu399)| false
• Search Google Scholar
• Export Citation

Rovin BH, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1–S276. doi: 10.1016/j.kint.2021.05.021

• PubMed
Rovin BH, KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1–S276. doi: 10.1016/j.kint.2021.05.021)| false
• Search Google Scholar
• Export Citation

Brix SR, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 2018; 94:1177–1188. doi: 10.1016/j.kint.2018.07.020

• PubMed
Brix SR, Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 2018; 94:1177–1188. doi: 10.1016/j.kint.2018.07.020)| false
• Search Google Scholar
• Export Citation

Floyd L, et al. Risk stratification to predict renal survival in anti-GBM disease. J Am Soc Nephrol (published online ahead of print November 29, 2022). doi: 10.1681/ASN.2022050581; https://journals.lww.com/jasn/Abstract/9900/Risk_Stratification_to_Predict_Renal_Survival_in.71.aspx

• PubMed
Floyd L, Risk stratification to predict renal survival in anti-GBM disease. J Am Soc Nephrol (published online ahead of print November 29, 2022). doi: 10.1681/ASN.2022050581; https://journals.lww.com/jasn/Abstract/9900/Risk_Stratification_to_Predict_Renal_Survival_in.71.aspx)| false
• Search Google Scholar
• Export Citation